An emerging treatment option for glaucoma: Rho kinase inhibitors

An emerging treatment option for glaucoma: Rho kinase inhibitors

Sean K Wang,1 Robert T Chang21Stanford University, Stanford, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USAAbstract: Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in phase II and III US Food and Drug Administ...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang SK, Chang RT
Format: article
Language:EN
Published: Dove Medical Press 2014
Subjects:
Ophthalmology
RE1-994
Online Access:https://doaj.org/article/6ad1cf805a8448588824577ee1627ab6
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:doaj.org-article:6ad1cf805a8448588824577ee1627ab6
record_format dspace
spelling oai:doaj.org-article:6ad1cf805a8448588824577ee1627ab62021-12-02T05:54:21ZAn emerging treatment option for glaucoma: Rho kinase inhibitors1177-5483https://doaj.org/article/6ad1cf805a8448588824577ee1627ab62014-05-01T00:00:00Zhttp://www.dovepress.com/an-emerging-treatment-option-for-glaucoma-rho-kinase-inhibitors-a16776https://doaj.org/toc/1177-5483 Sean K Wang,1 Robert T Chang21Stanford University, Stanford, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USAAbstract: Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoskeleton contractile tone of smooth muscle. This results in increased aqueous outflow directly through the trabecular meshwork, achieving lower intraocular pressures in a range similar to prostaglandins. There are also animal studies indicating that ROCK inhibitors may improve blood flow to the optic nerve, increase ganglion cell survival, and reduce bleb scarring in glaucoma surgery. Given the multiple beneficial effects for glaucoma patients, ROCK inhibitors are certainly a highly anticipated emerging treatment option for glaucoma.Keywords: ROCK inhibitors, actin cytoskeleton, aqueous dynamics reviewWang SKChang RTDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 883-890 (2014)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Wang SK
Chang RT
An emerging treatment option for glaucoma: Rho kinase inhibitors
description Sean K Wang,1 Robert T Chang21Stanford University, Stanford, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USAAbstract: Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoskeleton contractile tone of smooth muscle. This results in increased aqueous outflow directly through the trabecular meshwork, achieving lower intraocular pressures in a range similar to prostaglandins. There are also animal studies indicating that ROCK inhibitors may improve blood flow to the optic nerve, increase ganglion cell survival, and reduce bleb scarring in glaucoma surgery. Given the multiple beneficial effects for glaucoma patients, ROCK inhibitors are certainly a highly anticipated emerging treatment option for glaucoma.Keywords: ROCK inhibitors, actin cytoskeleton, aqueous dynamics review
format article
author Wang SK
Chang RT
author_facet Wang SK
Chang RT
author_sort Wang SK
title An emerging treatment option for glaucoma: Rho kinase inhibitors
title_short An emerging treatment option for glaucoma: Rho kinase inhibitors
title_full An emerging treatment option for glaucoma: Rho kinase inhibitors
title_fullStr An emerging treatment option for glaucoma: Rho kinase inhibitors
title_full_unstemmed An emerging treatment option for glaucoma: Rho kinase inhibitors
title_sort emerging treatment option for glaucoma: rho kinase inhibitors
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/6ad1cf805a8448588824577ee1627ab6
work_keys_str_mv AT wangsk anemergingtreatmentoptionforglaucomarhokinaseinhibitors
AT changrt anemergingtreatmentoptionforglaucomarhokinaseinhibitors
AT wangsk emergingtreatmentoptionforglaucomarhokinaseinhibitors
AT changrt emergingtreatmentoptionforglaucomarhokinaseinhibitors
_version_ 1718400176606937088

Similar Items